Surgecare's EIC Accelerator Project Targets Infection on Day One
Open colon surgery has the highest surgical site infection rate of any operation the EU's disease agency tracks, at 10.2% in 2023, and hospitals decide each day which of these patients can go home. Surgecare, a French company that trades as Surge, says it can see it coming in a blood sample drawn on the first day after surgery. Its test, PreCyte, reads how the immune system responds to the operation and turns it into an infection risk score that surgical teams could use to decide who leaves early and who stays under watch.
The EIC Accelerator selected the project, titled "PreCyte: enabling Day 1 discharge decisions in postoperative abdominal surgeries", from the 8 July 2026 cut-off, with a recommendation for blended finance, according to the EIC's announcement of 16 November 2026 and its list of selected companies. Selection is not a funding commitment: the EIC expects to finalise grant agreements within three months, and no PreCyte project appears in CORDIS on the day of the announcement. This article sets out what the project promises and what can already be checked.
Company file
- Legal entity
- SURGECARE (trading as Surge), a French SAS, SIREN 902 294 651
- Founded
- Created on 7 August 2021 in Paris; seat moved to Illkirch-Graffenstaden in 2022 and to Strasbourg in 2025
- Leadership
- Julien Hédou, president and CEO; co-founder Brice Gaudillière, associate professor of anaesthesiology at Stanford per the 2022 and 2024 funding releases
- Investors named in the press
- Eurazeo, Kima, Teampact, MH Innov', HCVC, Boutique Venture Partners, 50 Partners Santé, plus Bpifrance grants
- Staff
- 6 to 9 employees in the register's 2024 band; a team of 15 on the company website
- EIC project
- PreCyte, 8 July 2026 cut-off, blended finance recommended; no grant agreement published yet
- Regulatory status
- Not CE marked or FDA cleared, per the company
Reading the immune response to surgery
The PreCyte product page describes a standard blood draw on the first postoperative day, analysed by cytometry with a seven-marker panel and combined with clinical surgical data to produce an objective infection risk score "within 24 hours of surgery". The comparison the company chooses is with C-reactive protein, a standard blood marker of inflammation: on its validation set, it says, PreCyte gave on day one the predictive value that CRP reached four days later. The page gives no sensitivity, specificity or area-under-the-curve figure.
The science underneath comes from Gaudillière's laboratory at Stanford. In a prospective cohort of 41 patients undergoing non-cancer bowel resection, published in Annals of Surgery in March 2022 with Hédou among the authors, a model built from single-cell mass cytometry and plasma proteins on the first postoperative day separated the 11 patients who developed a surgical site complication from the 30 who did not, with an area under the curve of 0.86. A second paper, led by Hédou and published in Nature Biotechnology online in January 2024, describes Stabl, a method for picking a small, reliable set of biomarkers out of high-dimensional data; the company calls it its patented algorithm. A Stanford patent on generating a surgical risk score from multi-omics data, US 12,755,850 B2, lists Gaudillière and Hédou among its inventors, and Surge announced an exclusive licence to Stanford's technology in September 2022.
Before or after the operation
The timing of the test has moved in the company's descriptions. In April 2024 Le Journal des Entreprises reported that PreCyte predicts digestive complications up to six weeks before surgery, with more than 90% reliability by the company's account, and the ClinicalTrials.gov record of its validation study describes a preoperative score. The EIC project title and the current product page centre on a sample taken the day after surgery, with preoperative testing offered to track the effect of prehabilitation. The 2022 Stanford paper reported both: its preoperative model reached an area under the curve of 0.82.
The study that is meant to settle it
The validation study is SPRED, sponsored by Hôpital Foch in Suresnes with "surge2surgery" as collaborator. ClinicalTrials.gov records an actual start on 6 October 2022, primary completion on 29 November 2023, study completion on 27 January 2025, and 283 adults enrolled for colorectal, gastric, pancreatic and liver resections. The primary outcome is the score's performance, measured by F1 score and AUROC, at predicting superficial or deep surgical site infection within 30 days.
The sources disagree on its scale and start. The registry lists four sites: Pitié-Salpêtrière, Saint-Antoine and Saint Joseph in Paris, and Foch. The product page and the company's December 2025 announcement speak of five hospitals. The company's September 2022 release said the Foch study had started in spring 2022, while the registry gives October 2022.
The evidence
Only the smallest of three cohorts has published results
The 41-patient Stanford cohort is the only one with peer-reviewed results. The 283-patient SPRED study is complete but no results were found in PubMed or on ClinicalTrials.gov on 16 November 2026; the Penn pilot is a company target.
Rumer et al., Annals of Surgery, 2022; ClinicalTrials.gov NCT05523713; Surge, 15 December 2025.
What matters more is that the results are not public. A PubMed search on 18 November 2026 for papers by Franck Verdonk, who led the multicentre validation according to the company, found Surge-affiliated immune studies in other settings, such as pancreatic surgery and prehabilitation, but no paper reporting SPRED or another multicentre validation of an infection score; the only surgical site infection prediction paper among them was the 2022 Stanford study. The registry record posts no results. The figures in circulation, "up to three times higher" predictive capacity than existing solutions, attributed to initial results of the 283-patient trial in the company's March 2024 announcement as reported by Silicon Canals, and the CRP comparison on the product page, come from the company.
A small company with two homes
The French register tells a quieter story than the "Paris and Bay Area" on the company website. Annuaire des Entreprises lists SURGECARE as an active SAS with its seat at 91 route des Romains in Strasbourg and Julien Hédou as president. The BODACC announcements record its creation in Paris in August 2021 with €5,000 of variable capital, a move to Illkirch-Graffenstaden near Strasbourg registered in December 2022 with €50,000 of capital, a conversion to fixed capital of €99,948.88 and an increase to €101,948.88 in July 2024, and a further capital change with a move to Strasbourg in November 2025, to €101,958.38. Accounts were filed for 2022, 2023 and 2024. No turnover or result figure is published in the open register data reviewed on 16 November 2026, and the April 2024 trade report said the company had no revenue yet. The laboratory, per the same report, sits in Paris at Cochin hospital.
The record
Five years from registration to an EIC selection
Surgecare was registered in Paris in August 2021, moved its seat to Alsace in December 2022 and was selected for the EIC Accelerator from the 8 July 2026 cut-off; the PreCyte study closed recruitment in November 2023.
- Aug 2021Company registeredSurgecare is created in Paris as a variable-capital SAS with €5,000 of capital€5,000
- Mar 2022Stanford study in printAnnals of Surgery publishes the 41-patient cohort in which a day-one immune model predicted surgical site complications
- Sep 2022First round and licenceSurge announces a $2.6M round co-led by HCVC and Boutique Venture Partners and an exclusive Stanford licence$2.6M
- Oct 2022SPRED study startsHôpital Foch sponsors the multicentre study in major digestive surgery, with surge2surgery as collaborator
- Dec 2022Seat moves to AlsaceRegistration at the Strasbourg court after the seat moves to Illkirch-Graffenstaden
- Nov 2023Recruitment endsSPRED reaches its primary completion date with 283 patients enrolled
- Mar 2024€7.5M roundEurazeo leads the round; Le Journal des Entreprises splits it into €5.3M of equity and €2.2M from Bpifrance€7.5M
- Dec 2025US pilotSurge announces a PreCyte pilot at Penn Medicine with about 100 patients, run as a laboratory developed test by Incite Health
- Nov 2026Selected by the EICPreCyte is one of 35 projects selected from 453 full applications, recommended for blended finance
BODACC announcements for SIREN 902 294 651; ClinicalTrials.gov NCT05523713; BioSpace, 23 September 2022; Le Journal des Entreprises, 4 April 2024; Surge, 15 December 2025; EIC, 16 November 2026.
The money on record is private and national. Surge announced a $2.6M round co-led by HCVC and Boutique Venture Partners in September 2022, alongside a 2022 i-Lab grant, according to the release carried by BioSpace; Tech.eu called it a pre-seed round. In March 2024 it announced €7.5M led by Eurazeo, with Kima, Teampact and MH Innov' joining earlier backers, to open its SurgeLab and finish industrialising PreCyte, as Silicon Canals reported. Le Journal des Entreprises split that figure into €5.3M of equity and €2.2M of non-dilutive Bpifrance funding.
The money
A €7.5M round in 2024 followed a €2.5M start in 2022
Company-announced rounds as reported by the press, not added up here because the sources differ; the split of the 2024 round comes from Le Journal des Entreprises. The EIC has not published the grant amount for individual companies of this cut-off.
Le Journal des Entreprises, 4 April 2024; Silicon Canals, 28 March 2024; BioSpace, 23 September 2022. Values in € millions.
EU money is a newer element. A CORDIS search on 16 November 2026 for SURGECARE, Surge Care, surge2surgery and PreCyte returned no project, and sources reviewed on that date show no investment in the company announced by the EIC Fund. The EIC has not published individual grant amounts for this cut-off, and the company's news page, read on the same day, carries no announcement of the selection.
One of 35, and a European problem
The EIC received 453 full applications for the round, interviewed 88 companies and selected 35, with €84 million of proposed grants and 32 companies to be assessed for EIC Fund equity of up to €10 million each; France, Switzerland and Germany supplied the most companies, the announcement states.
The competition
35 selected from 453 full applications
The EIC took 88 companies to interview and selected 35, with €84M of proposed grants in total; Surgecare is one of the 35.
EIC, announcement of 16 November 2026.
The clinical problem is well documented in Europe. In the ECDC's surveillance report published on 7 July 2026, 12 EU member states and one EEA country reported 6,254 surgical site infections from 421,397 procedures in 2023, with the share of infected operations ranging from 0.4% in laminectomies to 10.2% in open colon surgery, the highest of the nine procedure types. To be sold as a diagnostic in the EU, the test will need CE marking under the In Vitro Diagnostic Medical Devices Regulation; the product page says it has none yet.
The first deployment is American. The company's December 2025 announcement describes a pilot at Penn Medicine, supervised by Jason D. Christie, with about 100 surgical patients expected over a year, and samples processed by Incite Health, a CLIA-certified laboratory industrialising PreCyte as a laboratory developed test for the US market. Sources reviewed on 16 November 2026 show no published result from that pilot and no equivalent clinical deployment in Europe.
What can be checked so far
- Selection for the EIC AcceleratorSelectedListed for blended finance in the EIC announcement of 16 November 2026; no grant agreement in CORDIS yet.
- Published science behind the scorePublished41-patient day-one model in Annals of Surgery, Stabl in Nature Biotechnology.
- Multicentre validation of PreCyteRun, not published283 patients enrolled and the study completed per ClinicalTrials.gov; no results posted or published by 16 November 2026.
- Clinical use in hospitalsPilot announcedPenn Medicine pilot of about 100 patients announced in December 2025; no outcome published.
- Day 1 discharge decisions in EuropeToo earlyNo CE marking, per the company's product page; the EIC project has not started.
What the company says
The first blood test to score surgical site infection risk within 24 hours of surgery, matching on day one what CRP shows on day four, with up to three times the predictive capacity of existing tools and a launch in the United States.
What the record shows
A 41-patient peer-reviewed study from Stanford, a completed but unpublished 283-patient French study, a 100-patient US pilot as a laboratory developed test, a small Strasbourg-registered company with €7.5M raised in 2024, and no CE marking.
Verdict
Surgecare brings the EIC a test rooted in a decade of published Stanford immunology and a clinical question that hospitals face every day: which patient can safely go home after abdominal surgery. The company has done the expensive part of validation by running a 283-patient multicentre study, but three years after recruitment ended its results remain unpublished, and the performance figures in circulation are the company's own. The EIC project will be judged on whether those results appear, whether the test earns CE marking, and whether European surgeons start acting on a day-one score.
The reporting is based on publicly available sources, listed below.
Sources
- EIC, European Innovation Council selects 35 deep tech companies for its Accelerator support, 16 November 2026, with the list of selected companies
- Annuaire des Entreprises, SURGECARE, SIREN 902 294 651
- BODACC, commercial announcements for SIREN 902 294 651, 2021 to 2025
- Surge, PreCyte product page, read 16 November 2026
- Surge, PreCyte launches in the United States, 15 December 2025
- Surge, news page, read 16 November 2026
- ClinicalTrials.gov, SPRED, NCT05523713
- Rumer et al., Integrated Single-cell and Plasma Proteomic Modeling to Predict Surgical Site Complications, Annals of Surgery, 2022
- Hédou et al., Discovery of sparse, reliable omic biomarkers with Stabl, Nature Biotechnology, 2024
- US 12,755,850 B2, Systems and methods to generate a surgical risk score and uses thereof
- BioSpace, Surge raises $2.6M, secures exclusive licensing agreement with Stanford, 23 September 2022
- Tech.eu, Making surgeries safer, French biotech Surge raises $2.6 million, 22 September 2022
- Silicon Canals, Paris-based Surge gets €7.5M, 28 March 2024
- Le Journal des Entreprises, Surge Care lève 7,5 millions d'euros, 4 April 2024
- EIC Fund portfolio
- ECDC, Healthcare-associated infections: surgical site infections, Annual Epidemiological Report for 2023, 7 July 2026
- Regulation (EU) 2017/746 on in vitro diagnostic medical devices
Industry
HealthIn vitro diagnostics
- Focus
- Immunoassays
- Diagnostic software
- Technologies
- Molecular biomarkers
- Artificial intelligence
- Keywords
- Abdominal surgery
- Wound infection
- Hospital-acquired infections
- Postoperative care
- Immune cells